Neurocrine appoints new regulatory head
This article was originally published in Scrip
Neurocrine Biosciences has named Malcolm Lloyd-Smith to its executive management team as chief regulatory officer. Prior to joining San Diego, California-based Neurocrine, Mr Lloyd-Smith was senior vice-president of regulatory affairs, quality and clinical, at Cadence Pharmaceuticals.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.